gemfibrozil has been researched along with c-peptide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colwell, JA; Vinik, AI | 1 |
| Kuusi, T; Lahdenperä, S; Taskinen, MR; Tilly-Kiesi, M; Vuorinen-Markkola, H | 1 |
| Backman, JT; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
3 trial(s) available for gemfibrozil and c-peptide
| Article | Year |
|---|---|
Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gemfibrozil; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Male; Middle Aged; Triglycerides | 1993 |
Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.
Topics: Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gemfibrozil; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Metformin; Middle Aged; Phospholipids; Placebos; Triglycerides | 1993 |
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Topics: Adult; Antifungal Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Glucose; C-Peptide; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gemfibrozil; Half-Life; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Itraconazole; Male; Piperidines | 2003 |